FDBK Feedback Plc

TIDMFDBK

RNS Number : 2189X

Feedback PLC

19 December 2023

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

Feedback plc

Feedback awarded pilot funding to undertake further CDC pathway development

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces it is conducting a series of pilot programmes of Community Diagnostic Centre ("CDC") care pathways funded by a combined award of GBP300,000. The Company has directly contracted with the individual NHS organisations hosting the pilot sites utilising funds locally disbursed for this purpose under NHS England's ("NHSE"), Community Diagnostic Centre Programme.

These pilots, which will initially run until 31 March 2024, will build on Feedback's pilot contract for the Sussex ICS with QVH and aim to further demonstrate the impact of a pathway approach on CDC utilisation and wider patient wait times. The pilot implementations will also facilitate GP Direct access into CDC diagnostic services.

Two pilot sites are participating in the programme - Amersham CDC in Buckinghamshire and a pan regional pilot across Buckinghamshire, Oxfordshire and Berkshire ICS (BOB ICS), looking at multiple service lines and mutual aid delivery models for sharing workforce capacity at a regional basis through the Bleepa platform.

The evidence generated by these pilots will build the case for subsequent funding of a pathway approach to CDC delivery in subsequent financial years and NHSE will be closely monitoring the pilot outcome data as the programme rolls out in order to inform forward planning.

Dr Tom Oakley, CEO of Feedback plc said: "We are delighted to have the opportunity to further build the evidence base for a pathway approach to CDCs using Bleepa. This will generate the results back into the clinical pathway, under the noses of decision makers and enable them to facilitate a robust clinical dialogue to transform results into care decisions.

"Bleepa has already demonstrated a 69% reduction in wait times through the power of asynchronous communication and a pathway approach with Queen Victoria Hospital in Sussex. This is the sort of impact data that will support the NHS to address elective care backlogs and to help ease winter pressures. It is a privilege to work with a number of new NHS partners to help them deliver this impact for their patients and staff.

"The team very much look forward to commencing these pilots and further strengthening our relationship with the NHS, which provides funding for a number of vanguard projects to champion the adoption and use of digital technology and innovation in care pathways."

--Ends--

Enquiries:

 
 Feedback plc                             +44 (0) 20 3997 7634 
  Tom Oakley, CEO                          IR@fbk.com 
  Anesh Patel, CFO 
 
 Panmure Gordon (UK) Limited 
  (NOMAD and Broker) 
  Emma Earl/Freddy Crossley (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking)      +44 (0)20 7886 2500 
 
 Walbrook PR Ltd;                         Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 
 Nick Rome/Joe Walker                     07748 325 236 or 07407 020 470 
 

About Feedback

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFVLLFXLLFFBV

(END) Dow Jones Newswires

December 19, 2023 02:00 ET (07:00 GMT)

Feedback (LSE:FDBK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Feedback (LSE:FDBK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024